Dashboard
Manage Tickers

XNCR Xencor Inc

Nasdaq xencor.com


$ 14.70 $ 0.42 (2.95 %)    

Wednesday, 29-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 634.74 $ 2.85 (0.45 %)
DIA $ 476.09 $ -0.78 (-0.16 %)
SPY $ 686.84 $ 0.33 (0.05 %)
TLT $ 90.87 $ -0.93 (-1.01 %)
GLD $ 363.50 $ -1.38 (-0.38 %)
$ 14.67
$ 15.24
$ 14.41 x 100
$ 16.26 x 145
$ 14.47 - $ 15.50
$ 6.92 - $ 27.24
1,748,993
na
1.05B
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-25-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-05-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-07-2018 03-31-2018 10-Q
31 02-28-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-02-2016 03-31-2016 10-Q
39 03-08-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

barclays-upgrades-xencor-to-overweight-raises-price-target-to-23
Barclays Upgrades Xencor to Overweight, Ra...
10/29/2025 12:11:13

Barclays analyst Etzer Darout upgrades Xencor (NASDAQ:XNCR) from Underweight to Overweight and raises the price target from ...

rbc-capital-maintains-outperform-on-xencor-raises-price-target-to-18
RBC Capital Maintains Outperform on Xencor...
10/27/2025 15:11:29

RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $15 to...

xencor-presents-initial-results-from-ongoing-phase-1-dose-escalation-study-of-xmab819-enpp3-x-cd3-t-cell-engaging-bispecific-antibody-in-patients-with-advanced-ccrcc-at-aacr-nci-eortc
Xencor Presents Initial Results From Ongoi...
10/24/2025 16:31:47

-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 17:06:11

xencor-to-present-initial-results-from-ongoing-phase-1-dose-escalation-study-of-xmab819-in-patients-with-ccrcc-at-aacr-nci-eortc-conference-2025
Xencor To Present Initial Results From Ong...
10/14/2025 16:47:31

-- Management to host webcast and conference call on Friday, October 24, 2025 --Xencor, Inc. (NASDAQ:XNCR), a clinical-stage bi...

cantor-fitzgerald-assumes-xencor-at-overweight-announces-price-target-of-40
Cantor Fitzgerald Assumes Xencor at Overwe...
10/06/2025 13:30:39

Cantor Fitzgerald analyst Steve Seedhouse assumes Xencor (NASDAQ:XNCR) with a Overweight rating and announces Price Target o...

b-of-a-securities-downgrades-xencor-to-neutral-lowers-price-target-to-12
B of A Securities Downgrades Xencor to Neu...
09/03/2025 15:51:39

B of A Securities analyst Alec Stranahan downgrades Xencor (NASDAQ:XNCR) from Buy to Neutral and lowers the price target fro...

beyond-the-numbers-4-analysts-discuss-xencor-stock
Beyond The Numbers: 4 Analysts Discuss Xen...
09/02/2025 21:00:21

wedbush-reiterates-outperform-on-xencor-maintains-26-price-target
Wedbush Reiterates Outperform on Xencor, M...
09/02/2025 15:20:01

Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $26 price target.

rbc-capital-maintains-outperform-on-xencor-lowers-price-target-to-15
RBC Capital Maintains Outperform on Xencor...
08/21/2025 14:17:06

RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $32 to...

wells-fargo-maintains-overweight-on-xencor-lowers-price-target-to-27
Wells Fargo Maintains Overweight on Xencor...
08/07/2025 14:47:12

Wells Fargo analyst Eva Fortea Verdejo maintains Xencor (NASDAQ:XNCR) with a Overweight and lowers the price target from $33...

wedbush-maintains-outperform-on-xencor-lowers-price-target-to-26
Wedbush Maintains Outperform on Xencor, Lo...
08/07/2025 12:39:42

Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $31 to ...

xencor-q2-eps-041-beats-072-estimate-sales-4361m-beat-2145m-estimate
Xencor Q2 EPS $(0.41) Beats $(0.72) Estima...
08/06/2025 20:43:03

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.72) by 43....

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
05/09/2025 21:06:23

barclays-maintains-underweight-on-xencor-lowers-price-target-to-6
Barclays Maintains Underweight on Xencor, ...
05/08/2025 16:43:02

Barclays analyst Peter Lawson maintains Xencor (NASDAQ:XNCR) with a Underweight and lowers the price target from $22 to $6.

xencor-q1-eps-066-misses-060-estimate-sales-3273m-beat-2241m-estimate
Xencor Q1 EPS $(0.66) Misses $(0.60) Estim...
05/07/2025 20:50:22

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.60) by 1...

Core News & Articles
'FDA Names Vinay Prasad as New Head of Vac...
05/06/2025 17:53:23

https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics

xencor-announces-positive-interim-results-from-first-in-human-healthy-volunteer-study-of-xmab942-a-high-potency-extended-half-life-anti-tl1a-antibody-for-treatment-of-inflammatory-bowel-disease
Xencor Announces Positive Interim Results ...
04/29/2025 20:02:44

-- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 ---- Sin...

william-blair-initiates-coverage-on-xencor-with-outperform-rating
William Blair Initiates Coverage On Xencor...
04/21/2025 15:24:09

William Blair analyst Matt Phipps initiates coverage on Xencor (NASDAQ:XNCR) with a Outperform rating.

wells-fargo-maintains-overweight-on-xencor-lowers-price-target-to-33
Wells Fargo Maintains Overweight on Xencor...
02/28/2025 17:22:44

Wells Fargo analyst Eva Fortea Verdejo maintains Xencor (NASDAQ:XNCR) with a Overweight and lowers the price target from $37...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION